Press Releases

Bioclinica Launches COVID-19 Clinical Endpoint Adjudication Solution

Bioclinica has introduced a specialized program for the adjudication of adverse events that could result from COVID-19 infection. Bioclinica's new program provides an out-of-the-box Clinical Endpoint Committee solution. This solution combines world-class medical expertise, an experienced adjudication management team,...

Medivant Launches Pharma Mfg. Ops in US

A new U.S.-based pharmaceutical manufacturer, Tailstorm Health, Inc., DBA Medivant Healthcare, will begin to roll out sterile single dose liquid injectable medications on the FDA's Drug Shortage List. Medivant's initial products will include sterile liquid injectables that are in...

Catalent Partners with Humanigen to Support FDA-Approved Phase 3 Lenzilumab Study for COVID-19

Catalent, a global leader in clinical supply services, welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating...

Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India’s drug regulator DCGI in late April. Glenmark is the first company in...

Digital Science reports that just 10% of global research output relates to the UN’s Sustainable Development Goals

Digital Science, a leading technology company serving emergent needs across the research sector, has released a report highlighting the growth in research around the UN’s Sustainable Development Goals (SDGs). The report Contextualizing Sustainable Development Research, which was produced by Digital...

Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

Pfizer Inc. and BioNTech SE announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program,...

Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read